AIMS: The objective was to implant a stented decellularised tissue-engineered heart valve (sdTEHV) percutaneously in an animal model, to assess its in vivo functionality and to examine the repopulation and remodelling of the valvular matrix by the recipient's autologous cells. METHODS AND RESULTS: Prototypes of sdTEHV were cultured in vitro, decellularised and percutaneously implanted into the pulmonary position in 15 sheep. Functionality was assessed monthly by intracardiac echocardiography (ICE). Valves were explanted after eight, 16 or 24 weeks and analysed macroscopically, histologically and by electron microscopy. Implantation was successful in all animals. Valves showed normal pressure gradients throughout the study. Due to a suboptimal design with small coaptation area, stent ovality led to immediate regurgitation which continuously increased during follow-up. Analyses revealed complete endothelialisation and rapid cellular repopulation and remodelling of the entire matrix. Valves were free from endocarditis, calcification and graft rejection. CONCLUSIONS: sdTEHV can be safely implanted percutaneously. The fast autologous recellularisation and the extensive matrix remodelling demonstrate the valve's potential as a next-generation percutaneous prosthesis with the capacity for tissue self-maintenance and longevity. Regurgitation may be prevented by valve design optimisation.
AIMS: The objective was to implant a stented decellularised tissue-engineered heart valve (sdTEHV) percutaneously in an animal model, to assess its in vivo functionality and to examine the repopulation and remodelling of the valvular matrix by the recipient's autologous cells. METHODS AND RESULTS: Prototypes of sdTEHV were cultured in vitro, decellularised and percutaneously implanted into the pulmonary position in 15 sheep. Functionality was assessed monthly by intracardiac echocardiography (ICE). Valves were explanted after eight, 16 or 24 weeks and analysed macroscopically, histologically and by electron microscopy. Implantation was successful in all animals. Valves showed normal pressure gradients throughout the study. Due to a suboptimal design with small coaptation area, stent ovality led to immediate regurgitation which continuously increased during follow-up. Analyses revealed complete endothelialisation and rapid cellular repopulation and remodelling of the entire matrix. Valves were free from endocarditis, calcification and graft rejection. CONCLUSIONS: sdTEHV can be safely implanted percutaneously. The fast autologous recellularisation and the extensive matrix remodelling demonstrate the valve's potential as a next-generation percutaneous prosthesis with the capacity for tissue self-maintenance and longevity. Regurgitation may be prevented by valve design optimisation.
Authors: Petra E Dijkman; Emanuela S Fioretta; Laura Frese; Francesco S Pasqualini; Simon P Hoerstrup Journal: Transfus Med Hemother Date: 2016-07-26 Impact factor: 3.747
Authors: Sarah E Motta; Emanuela S Fioretta; Petra E Dijkman; Valentina Lintas; Luc Behr; Simon P Hoerstrup; Maximilian Y Emmert Journal: J Cardiovasc Transl Res Date: 2018-03-20 Impact factor: 4.132
Authors: V Lintas; E S Fioretta; S E Motta; P E Dijkman; M Pensalfini; E Mazza; E Caliskan; H Rodriguez; M Lipiski; M Sauer; N Cesarovic; S P Hoerstrup; M Y Emmert Journal: J Cardiovasc Transl Res Date: 2018-08-13 Impact factor: 4.132
Authors: Sarah E Motta; Emanuela S Fioretta; Valentina Lintas; Petra E Dijkman; Monika Hilbe; Laura Frese; Nikola Cesarovic; Sandra Loerakker; Frank P T Baaijens; Volkmar Falk; Simon P Hoerstrup; Maximilian Y Emmert Journal: Sci Rep Date: 2020-11-16 Impact factor: 4.379